Insulin Biosimilars Demand to Grow Significantly, States DelveInsight in Its New Research Report Available at MarketPublishers.com22 Mar 2017 • by Natalie Aster
LONDON – Biosimilars have drawn a great deal of attention from market players due to the latest technological innovations, novel regulations in the biopharma industry, and cost concerns, among others. In reality, efforts are already being made to develop a novel class of follow-on biologic drugs such as biobetters (biosuperiors).
The prospects of insulin biosimilars such as Basaglar is enormous in the offing, the demand is expected to grow at a significant pace in developed marketplaces as the countries such as the USA, Europe and Japan have exhibited a great enthusiasm toward biosimilars, particularly Europe. The developed market space, apart from the USA, has represented the most prominent biosimilars presence nowadays.
The better half of biosimilars producers have been and stay focused on the developed markets whether it is for their historical and present-day opportunities (the EU) or for their upcoming market potential (the USA and Japan).
New research study “Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2017” elaborated by DelveInsight examines the therapeutics development for the worldwide insulin marketplace.
The report covers insulin biosimilar pipeline from pole to pole. It offers sales figures for marketed insulin during 2015-2017. The study contains detailed insights into the description of the product and the related phase of development, therapy mode, MoA, implementation partner and technology details. The research gives an overview of the biosimilar regulatory environment of different markets encompassing developed markets of the USA and the EU. The report offers an analysis of the vital and various types of insulin under development, covering their market share and length of activity. Furthermore, the study identifies emerging players with potentially robust product range the top players of the most up-and-coming pipeline. The report sheds light on the potential leaders in the insulin biosimilar marketplace.
More in-demand research studies by this publisher are available at DelveInsight page.